The Fort Worth Press - Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Access the interviews in their entirety at:

• PCSA: https://www.redchip.com/assets/access/pcsa_access

• BFRG: https://www.redchip.com/assets/access/bfrg_access.html

In an exclusive interview, George Ng, CEO of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how Processa is redefining oncology drug development by transforming existing chemotherapy agents into safer, more effective Next Generation Cancer (NGC) therapies. Ng highlights the company's lead asset, PCS6422 (NGC-Cap), now enrolling patients in a Phase 2 trial for metastatic breast cancer, and shares how Processa's Regulatory Science Approach positions it to generate superior tumor-targeting drugs with significantly reduced toxicity. He also discusses the company's recent $7M capital infusion, value-driving partnership with Intact Therapeutics for PCS12852, and its strategic pipeline realignment to prioritize assets with strong commercial and regulatory potential. With multiple near-term catalysts and a capital-efficient model, Processa offers a compelling microcap investment opportunity in the oncology space.

Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how BullFrog is redefining drug development through its enterprise-ready AI platform, BullFrog Data Networks™, powered by the proprietary bfLEAP™ engine. Singh explains how the company's multimodal, causal AI technology enables life sciences companies to uncover novel drug targets, optimize clinical trials, and repurpose existing therapies-dramatically reducing development costs and timelines. He highlights BullFrog's recent commercial expansion through a strategic alliance with global CRO Sygnature Discovery, expected to generate up to $30 million in revenue by 2028, as well as exclusive research collaborations with institutions like the J. Craig Venter Institute and Lieber Institute. With a scalable, cloud-deployable platform and a business model built for recurring software revenue, BullFrog AI offers investors a unique opportunity at the intersection of biotech and next-generation artificial intelligence.

PCSA and BFRG are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Processa Pharmaceuticals, Inc.

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path. In addition to its core oncology programs, Processa is actively pursuing strategic partnerships for non-oncology assets to unlock additional value

For more information, visit our website at www.processapharma.com.

About BullFrog AI

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit BullFrog AI at: https://bullfrogai.com

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]

--END--

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire

N.Patterson--TFWP